Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

View Full Paper
Ask AI
Bookmark
Share

Authors

TSTaylor SchwartzSASusan M. AdamsANAhmad Naim

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals ruxolitinib treatment duration averages 3.1 years in myelofibrosis patients, suggesting effective management strategies.

Key Points

  • Patients receiving ruxolitinib treatment for myelofibrosis showed a median duration of 37 months, indicating long-term effectiveness.
  • In this cohort of 2268 patients, transfusion requirements decreased significantly for those previously needing transfusions.
  • Retrospective analysis utilizing Medicare claims data assessed treatment duration and anemia management across various comorbidities.
  • These findings imply that effective dose optimization of ruxolitinib supports prolonged treatment for myelofibrosis patients with anemia.

Cite This Study

Schwartz et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5b1https://doi.org/10.1182/blood-2025-6391
View Full Paper
Ask AI
Bookmark
Share